James Investment Research Inc. acquired a new stake in LivaNova PLC (NASDAQ:LIVN) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 24,920 shares of the company’s stock, valued at approximately $1,992,000.

Several other hedge funds have also recently added to or reduced their stakes in LIVN. PNC Financial Services Group Inc. lifted its position in LivaNova by 9.8% during the second quarter. PNC Financial Services Group Inc. now owns 1,707 shares of the company’s stock valued at $105,000 after purchasing an additional 153 shares during the last quarter. Strs Ohio lifted its position in LivaNova by 2.9% during the fourth quarter. Strs Ohio now owns 21,100 shares of the company’s stock valued at $1,686,000 after purchasing an additional 600 shares during the last quarter. Thrivent Financial For Lutherans lifted its position in LivaNova by 7.6% during the second quarter. Thrivent Financial For Lutherans now owns 8,770 shares of the company’s stock valued at $537,000 after purchasing an additional 620 shares during the last quarter. Riverhead Capital Management LLC lifted its position in LivaNova by 76.3% during the second quarter. Riverhead Capital Management LLC now owns 1,763 shares of the company’s stock valued at $108,000 after purchasing an additional 763 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in LivaNova by 1.3% during the third quarter. Rhumbline Advisers now owns 94,714 shares of the company’s stock valued at $6,636,000 after purchasing an additional 1,189 shares during the last quarter. Institutional investors own 86.03% of the company’s stock.

Several equities research analysts have issued reports on LIVN shares. ValuEngine upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a research report on Thursday, November 2nd. Canaccord Genuity reiterated a “hold” rating and set a $76.00 target price on shares of LivaNova in a research report on Tuesday, December 5th. Piper Jaffray Companies reiterated a “buy” rating and set a $85.00 target price on shares of LivaNova in a research report on Friday, November 3rd. Needham & Company LLC lifted their target price on shares of LivaNova from $93.00 to $97.00 and gave the company a “buy” rating in a research report on Tuesday, December 5th. Finally, Zacks Investment Research lowered shares of LivaNova from a “hold” rating to a “strong sell” rating in a research report on Thursday. Two analysts have rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company’s stock. LivaNova currently has an average rating of “Hold” and an average target price of $79.71.

In other LivaNova news, Director Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $82.15, for a total transaction of $82,150.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Alfred J. Novak sold 2,000 shares of LivaNova stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $85.77, for a total transaction of $171,540.00. The disclosure for this sale can be found here. Insiders have sold 6,830 shares of company stock worth $576,920 over the last three months. Insiders own 0.28% of the company’s stock.

LivaNova PLC (NASDAQ:LIVN) opened at $87.55 on Monday. The company has a market cap of $4,180.00 and a P/E ratio of 23.35. LivaNova PLC has a one year low of $45.67 and a one year high of $88.56. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.42 and a current ratio of 2.03.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Thursday, November 2nd. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.76 by $0.17. The firm had revenue of $309.70 million for the quarter, compared to the consensus estimate of $301.22 million. LivaNova had a net margin of 4.63% and a return on equity of 9.33%. The business’s revenue was up 4.9% compared to the same quarter last year. During the same period last year, the firm posted $0.78 earnings per share. sell-side analysts predict that LivaNova PLC will post 2.93 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2018/01/29/james-investment-research-inc-acquires-shares-of-24920-livanova-plc-livn.html.

About LivaNova

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.

Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN).

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.